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FARP2 is a Dbl-family guanine nucleotide exchange
factor (GEF) that contains a 4.1, ezrin, radixin and
moesin (FERM) domain, a Dbl-homology (DH)
domain and two pleckstrin homology (PH) domains.
FARP2 activates Rac1 or Cdc42 in response to
upstream signals, thereby regulating processes
such as neuronal axon guidance and bone homeo-
stasis. How theGEF activity of FARP2 is regulated re-
mained poorly understood. We have determined the
crystal structures of the catalytic DH domain and the
DH-PH-PH domains of FARP2. The structures reveal
an auto-inhibited conformation in which the GEF
substrate-binding site is blocked collectively by the
last helix in the DH domain and the two PH domains.
This conformation is stabilized by multiple interac-
tions among the domains and two well-structured
inter-domain linkers. Our cell-based activity assays
confirm the suppression of the FARP2 GEF activity
by these auto-inhibitory elements.
INTRODUCTION
FARP2 and its close homolog FARP1 are large multidomain
proteins sharing the same domain structures, after which they
are named (FERM, RhoGEF, and pleckstrin homology domain
proteins). FARP2 is also known as the FERM domain-including
RhoGEF (FIR) and the FGD1-related Cdc42-GEF (FRG) (Kubo
et al., 2002; Miyamoto et al., 2003). FARP1 is also known as
a chondrocyte-derived ezrin-like protein (CDEP) and pleckstrin
homology domain-containing family C member 2 (PLEKHC2)
(Koyano et al., 1997). Functional studies of FARP1 and FARP2
have been focused primarily on their roles in regulation of
neuronal development and morphology, motivated by their
abundant expression both in neurons at the developmental
stage and in the adult brain (Kawakita et al., 2003; Koyano
et al., 1997; Kubo et al., 2002; Murata et al., 2006). FARP1 and
FARP2 have been shown to interact directly with the neuronal
axon guidance receptors plexins, thereby participating in the
plexin signaling pathways that regulate dendrite outgrowth and
axon guidance, respectively (Toyofuku et al., 2005; Zhuang
et al., 2009). Recently, FARP2 has been found to be involved inStructure 21,the plexin-mediated regulation of bone homeostasis (Hayashi
et al., 2012; Takegahara et al., 2010).
FARPs contain the tandem Dbl-homology (DH) and pleckstrin
homology (PH) domains characteristic of the Dbl-family guanine
nucleotide exchange factors (GEFs) for RhoGTPases (Rossman
et al., 2005). Similar to other Dbl-family GEFs, FARPs contain
multiple extra domains in addition to the DH-PH module. The
N-terminal 4.1, ezrin, radixin, and moesin (FERM) domain is
linked to the DH domain by a 200-residue linker of low-
sequence complexity. They also have a second PH domain
(referred to as PH2), which is connected to the first PH domain
(PH1) by a 70-residue linker. Although FARP1 and FARP2
share a high degree of sequence identity (60% excluding the
FERM/DH linker), previous studies have suggested that they
act on different RhoGTPases for signal transduction. FARP1
has been identified as a RhoA GEF (Koyano et al., 2001),
whereas the substrate specificity of FARP2 remains ambiguous.
Two studies have reported that FARP2 is a GEF for Rac1 but not
for RhoA or Cdc42 (Kubo et al., 2002; Toyofuku et al., 2005),
whereas several others have shown that FARP2 is exclusively
active toward Cdc42 (Fukuhara et al., 2004; Fukuyama et al.,
2005; Miyamoto et al., 2003; Murata et al., 2006).
The DH domain in all the Dbl-family RhoGEFs is responsible
for catalyzing guanosine triphosphate (GTP)/GDP exchange,
through interacting with the guanine nucleotide-binding switch
I and II regions in the RhoGTPase and thereby ejecting the bound
guanine nucleotide (Rossman et al., 2005). The PH domain in the
conserved DH-PH module of many RhoGEFs regulates GEF
activity through interactions with the DH domain and/or the
RhoGTPase substrate (Chhatriwala et al., 2007; Derewenda
et al., 2004; Kristelly et al., 2004; Lutz et al., 2007; Rossman
et al., 2002, 2003). The composition and organization of domains
outside of the DH-PH module diverge greatly among the 70
Dbl-family RhoGEFs (Rossman et al., 2005). These extra
domains provide additional diverse mechanisms for regulating
the catalytic activity of the DH domain (Ahmad and Lim, 2010;
Bielnicki et al., 2011; Chen et al., 2011; Chrencik et al., 2008;
Mitin et al., 2007; Murayama et al., 2007; Rapley et al., 2008; Sol-
ski et al., 2004; Yohe et al., 2007, 2008; Yu et al., 2010; Zheng
et al., 2009).
The domain structure of FARP1 and FARP2 is distinct in the
Dbl family, and their regulation mechanisms are poorly under-
stood because of a lack of structural studies. Previous studies
have shown that the interactionwith plexins and phosphorylation
by the Src kinase regulate the GEF activity of FARPs, but the355–364, March 5, 2013 ª2013 Elsevier Ltd All rights reserved 355
Figure 1. Structure of the DH Domain of FARP2
(A) Overall structure of the DH domain. Helix a6C is colored in yellow. The side chains of Leu730 and Leu733 and neighboring residues are shown in stick-and-dot
representations.
(B) Superimposition of the FARP2 DH domain with the intersectin/Cdc42 complex (PDB ID code: 1KI1). The PH domain in intersectin is omitted for clarity. Helix
a6C in FARP2 resembles the switch II helix (dark blue) of Cdc42. Leu730 and Leu733 occupy the same positions as Leu67 and Leu70 in Cdc42, respectively. Two
substitutions (His690 and Gln727 in FARP2) in the substrate-binding surface of the DH domain are highlighted.
(C) Comparison of the kinked helices a6C in the DH domains of FARP2, FGD5, and SOS.
(D) Sequence alignment of the DH domains of mouse FARP2, human FARP1, and human intersectin. The stars highlight the positions of Leu730 and Leu733 in
FARP2. The triangles mark the two key substitutions in the substrate-binding site in FARP2 (His690 and Gln727).
See also Figure S1.
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Crystal Structures of Autoinhibited FARP2detailed mechanism for these regulation processes are not
known (Fukuhara et al., 2004; Fukuyama et al., 2005; Miyamoto
et al., 2003; Murata et al., 2006; Toyofuku et al., 2005; Zhuang
et al., 2009). We have determined crystal structures of the DH
domain and the DH-PH-PH domains of FARP2 at 2.9 and
3.2 A˚, respectively, and a 4.1 A˚ structure of the DH-PH-PH
domains of FARP1. The structures reveal a multilayered autoin-
hibition mechanism that involves the C-terminal portion of the
last helix in the DH domain, the two PH domains, and two inter-
domain linkers. This autoinhibited conformation is distinct from
those of other RhoGEFs characterized by previous structural
studies. The results of our cell-based GEF assays support
the regulation of the FARP2 activity by this autoinhibition
mechanism.
RESULTS AND DISCUSSION
Autoinhibition of the DH Domain by Helix a6
The structure of the DH domain of mouse FARP2 displays the
typical DH domain fold of an elongated 6-helix bundle (Figure 1A;
Table 1). A protein structure database search using the Dali
server suggested that it is most similar to the DH domain of
intersectin, a Cdc42-specific GEF (Holm et al., 2008). However,356 Structure 21, 355–364, March 5, 2013 ª2013 Elsevier Ltd All righFARP2 shows an unexpected conformational difference in the
last helix in the DH domain (helix a6). Although helix a6 in
many other DH domain structures is largely straight, helix a6 in
FARP2 undergoes a sharp kink of 60 between Leu726 and
Gln727. The consequent direction change positions the
C-terminal portion of helix a6 (referred to as helix a6C) in the
groove between helices a3 and a5. The asymmetric unit of our
crystal contains nine protomers of the FARP2 DH domain, which
all exhibit the same kinked conformation of helix a6, supporting
that this conformation is not induced by a particular set of crystal
contacts (Figure S1 available online).
A superimposition of the FARP2 DH domain with the structure
of intersectin bound to its substrate Cdc42 (Protein Data Bank
[PDB] ID code: 1KI1) revealed that part of helix a6C closely
resembles the helical segment in switch II of Cdc42 (Figure 1B)
(Snyder et al., 2002). Particularly, Leu730 and Leu733 in helix
a6C superimpose well with Leu67 and Leu70 in Cdc42 and
make similar interactions with the hydrophobic groove between
helices a3 and a5 in the DH domain. The interface between the
switch II helix and the DH domain is a conserved feature that is
essential for the exchange activity (Rossman et al., 2005). Helix
a6C in FARP2 therefore acts as a pseudosubstrate-like inhibitor
of the GEF activity. Helix a6C in the DH domain of son ofts reserved
Table 1. Data Collection and Refinement Statistics
Data Collection
Data set FARP2 DH Seleno-methionine SAD FARP2 DH-PH-PH Native FARP1 DH-PH-PH
Seleno-methionine SAD
Beamline APS, 19ID APS, 19ID APS, 19ID
Wavelength (A˚) 0.97935 0.97935 0.97915
Space group C2221 C2 P31
Unit cell (A˚, ) a = 121.2, b = 210.0,
c = 325.0
a = 184.4, b = 85.2,
c = 103.5, b = 118.8
a = 142.2, b = 142.2,
c = 105.2, b = 120
Resolution (A˚)a 50–2.90 (3.0–2.9) 50–3.20 (3.26–3.20) 50–4.10 (4.17–4.1)
Number of reflections 912,784 95,170 143,688
Number of unique reflections 91,570 (9,061) 23,250 (1,174) 18,675 (917)
Completeness (%) 99.9 (100) 99.7 (99.9) 99.5 (97.7)
I/s 39.6 (3.0) 18.0 (2.3) 36.7 (3.4)
Rsym (%) 8.4 (79.6) 11.1 (75.0) 10.7 (50.6)
Refinement
Rwork/Rfree (%) 17.78/22.12 23.21/27.79 27.63/31.88
Protomers/asymmetric unit 9 2 2
Number of protein atoms 15,716 6,705 5,955
Number of water 17 19 0
Average B-factor (A˚2) 90.4 108.0 195.7
Average B-factor, protein (A˚2) 90.5 108.2 195.7
Average B-factor, water (A˚2) 67.7 30.7 –
Rmsd bond length (A˚) 0.0095 0.0068 0.0038
Rmsd bond angle () 1.1745 1.0054 0.718
Ramachandran plot (favored,
allowed, disallowed) (%)
95.6, 4.3, 0.1 93.1, 6.9, 0 91.9, 7.6, 0.5
PDB ID code 4GYV 4GZU 4H6Y
Rmsd, root-mean-square deviation.
aNumbers in parentheses refer to the highest resolution shell.
Structure
Crystal Structures of Autoinhibited FARP2sevenless (SOS) (PDB ID code: 1DBH) and faciogenital dysplasia
gene product 5 (FGD5) (PDB ID code: 3MPX) also adopts kinked
conformations (Soisson et al., 1998) (Figure 1C). However, in
those cases the kink is more acute, and helix a6C interacts
with the middle portion of helix a5 and does not resemble the
RhoGTPase substrate. To the best of our knowledge, no detailed
mutational analyses of the inhibitory role of helix 6aC in SOS and
FGD5 have been reported.
The structure comparison with intersectin also revealed that
the FARP2 DH domain contains substitutions of several con-
served residues that are known to be important for RhoGTPase
binding and the GEF activity. Most DH domains have a lysine or
arginine residue in helix a5 (Arg1384 in intersectin), which makes
electrostatic interactions with both switches I and II in the
RhoGTPase (Figures 1B and 1D). The corresponding position
in FARP2 and its close homolog FARP1 is a histidine (His690
and His691, respectively) (Figures 1B and 1D). Gln727 in helix
a6 of the FARP2 DH domain replaces a highly conserved aspar-
agine in other DH domains (Asn1421 in intersectin). The aspara-
gine residue makes critical contributions to the GEF activity by
forming hydrogen bonds with the N-terminal end of the switch
II helix in the RhoGTPase substrate. The longer side chain of
Gln727 in FARP2 may clash with the switch II helix unless the
interface undergoes an adjustment. The equivalent residue inStructure 21,FARP1 is a histidine (His728), representing a further deviation.
These substitutions of key residues suggest that FARPs diverge
from typical DH domains and have compromised active sites,
which may partially explain the lack of activity in our in vitro
assays (see below).
Overall Structure of the DH-PH-PH Domains
To uncover the organization of the tandem PH domains in rela-
tion to the DH domain and their potential regulation of the GEF
activity, we determined the structure of the DH-PH-PH domains
of mouse FARP2 at 3.2 A˚ resolution (Figure 2). We also deter-
mined the structure of the DH-PH-PH domains of human
FARP1 at 4.1 A˚ resolution, which is very similar to that of
FARP2 (Figure S2). The following discussion will be focused on
the higher resolution FARP2 structure unless otherwise stated.
Helix a6C in the DH-PH-PH structure of FARP2 adopts the
kinked conformation similar to that in the isolated DH domain,
although it tilts more toward and interacts more intimately with
the main body of the DH domain (Figures 2B and 2C). This
may be a result of the interactions between PH2 and the DH
domain, which pull helix a6C indirectly through PH1 toward the
DH domain. The FARP1 structure exhibits the same kinked helix
a6C, whichmakes similar hydrophobic interactions with themain
body of the DH domain (Figure S2).355–364, March 5, 2013 ª2013 Elsevier Ltd All rights reserved 357
Figure 2. Structure of the DH-PH-PH Domains of FARP2
(A) Schematic of the domain structure of FARP2.
(B) Overall structure of the DH-PH-PH domains. The color scheme is the same as in (A). Dashed lines represent disordered loops in the structure.
(C) Comparison of the DH structures in the DH-PH-PH domains (DH, cyan; helix a6C, yellow) and the isolated DH domain (gray). The structures are rotated
horizontally in relation to (B) by 90.
(D) Blocking of the substrate-binding site by helix a6C, PH1, PH2, and the PH1-PH2 linker. Cdc42 (blue semitransparent surface) is docked by superimposing the
intersectin/Cdc42 complex structure (PDB ID code: 1KI1) on to the FARP2 DH-PH-PH structure. Intersectin is omitted for clarity.
See also Figure S2.
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Crystal Structures of Autoinhibited FARP2Similar to many other DH-PH modules, the first PH domain
(PH1) in FARPs interacts extensively with helix a6C (Figure 2B).
The second PH domain (PH2) forms a large interface with the
DH domain by docking onto the RhoGTPase binding surface.
The C-terminal portion of the 70-residue linker between PH1
and PH2 (the PH1-PH2 linker) forms a well-defined structure
motif and interacts with both the PHdomains. These interdomain
interactions hold the DH-PH-PH domains together to adopt
a highly compact structure. A superimposition with the intersec-
tin/Cdc42 complex structure shows that the entire substrate-
binding site in the DH domain of FARP2 is occupied collectively
by helix a6C, the two PH domains and the PH1-PH2 linker
(Figure 2D).
Our three structures together demonstrate that FARP1 and
FARP2 use a conserved autoinhibition mechanism that involves
both helix a6C in the DH domain and the tandem PH domains.
The autoinhibition is stabilized by the multiple interactions
among the domains and the interdomain linkers. Activation of
the GEF activity would require a large-scale conformational
change that removes these autoinhibitory elements from the
active site of the DH domain.
Structure of PH1 and Its Interactions with the DH
Domain
PH1 adopts the typical PH domain fold characterized by
a seven-strand b sandwich that is covered at one side by a C-ter-
minal helix (Figure 3A). It is connected to helix a6 in the DH
domain by the 14-residue linker (the DH-PH1 linker) that is highly
conserved between FARP1 and FARP2 (Figures 3A and 3C). The
surface of the b sheet formed by strands b1–b4 contains a large
number of hydrophobic residues, including Phe779, Phe781,
Met784, Leu786, and Ile800. These residues together with the
conserved nonpolar residues in the DH-PH1 linker make358 Structure 21, 355–364, March 5, 2013 ª2013 Elsevier Ltd All righhydrophobic interactions with the outward-facing side of helix
a6C in the DH domain (Figure 3B). The interface also includes
several hydrogen bonds and charge/charge interactions. These
interactions fix the position of PH1 in relation to the DH domain
such that it occupies part of the space for binding of the
RhoGTPase substrate (Figure 2D). Helix a6C, PH1, and the DH-
PH1 linker held together by these interactions likely swing
away from the DH domain as one rigid body when FARP2
undergoes activation.
PH domains in many RhoGEFs bind phosphatidylinositol
mono- or poly-phosphates [PtdInsP(s)] and thereby recruit the
proteins to specific membrane compartments where their
RhoGTPase substrates reside (Viaud et al., 2012). The typical
binding site is located near the loop between strands b1 and
b2, which contains several positively charged residues that
make electrostatic interactions with the negatively charged
phosphoinositide head group (Ferguson et al., 2000). PH1 in
FARP2 has seven lysine or arginine residues at the potential
binding site, which are mostly conserved in FARP1 (Figures
3A, 3C, and S3A). Interestingly, strong difference electron
density is present at this site in the FARP2 DH-PH-PH structure,
demonstrating binding of a certain compound (Figure S3B). The
compound was probably from the expression host Escherichia
coli BL21 (DE3) strain and was bound to and cocrystallized
with the FARP2 protein. The identity of the compound is not
known at present, although it is likely negatively charged given
the environment of the site. Regardless, these observations
together support that PH1 is capable of binding PtdInsP(s) and
facilitating membrane localization of FARPs.
The PH1-PH2 Linker
The 70-residue PH1-PH2 linker is disordered, except for the
864–868 and the 907–931 segments. The 864–868 segmentts reserved
Figure 3. Structure of PH1 and Its Interac-
tions with Helix a6C and the DH-PH1 Linker
(A) Overall structure of PH1 (light brown) together
with helix a6C (yellow), the DH-PH1 linker (green),
and the PH1-PH2 linker (blue). Positively charged
residues in the potential PtdInsP(s) binding site are
highlighted. The side chain of Lys831 is not built
because of a lack of electron density.
(B) Interactions among PH1, helix a6C, and the
DH-PH1 linker.
(C) Sequence alignment of mouse FARP2 and
human FARP1, starting from the DH-PH1 linker
and ending at the C terminus of PH2. The struc-
tured linker regions are highlighted by boxes,
colored as in (A). Secondary structural elements
are assigned based on the DH-PH-PH structure of
FARP2.
See also Figure S3.
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Crystal Structures of Autoinhibited FARP2adopts an extended conformation and docks onto the groove
between the DH-PH1 linker and strand b4 in PH1 (Figure 3A).
These interactions may not form in FARP1 because no density
is present in the same area in the FARP1 structure and the equiv-
alent segment (the 867–870 segment) is not conserved (Fig-
ure 3C). In contrast, the 907–931 segment in FARP2 shows
a high degree of sequence identity with the 909–933 segment
in FARP1 (Figure 3C). This segment forms a well-ordered helix-
strand-helix motif and is sandwiched between PH1 and PH2 in
both the FARP1 and the FARP2 structures (Figures 2B, 4, and
S2). In the first helical segment, Met910, Cys913, and Trp914
interact with the part of the b1–b4 surface in PH1 adjacent to
the area contacting helix a6C (Figures 3A and 4A). The interaction
with PH1 is further strengthened by two hydrogen bonds (Fig-
ure 4A). The other side of this helix interacts with the b2–b3,
b4–b5, and b6–b7 loops in PH2. The interface includes Van der
Waals interactions formed by Val912 with Pro975 and Leu977
and two hydrogen bonds between the side chain of Arg916
and two main-chain carbonyls in PH2. The middle strand
segment (residues 918–921) of the linker joins the b1–b4 sheet
in PH1 and turns it into a five-strand sheet (Figure 4B). The
second helical segment in the linker connects directly to strand
b1 in PH2 and interacts with all the three domains (Figure 4B).
At the N-terminal end, Arg922 forms hydrogen bonds with the
main-chain carbonyl of Phe759 and the side chain of Glu758 in
PH2. One side of the helix packs against the middle portion of
helices a5 and a6 in the DH domain (Figure 5A), whereas the
opposite side packs against the b2–b3 loop in PH2 (Figure 4B).
These interactions made by the PH1-PH2 linker effectively glueStructure 21, 355–364, March 5, 2013the two PH domains together, coupling
these two inhibitory elements for stronger
inhibition of the DH domain.
Structure of PH2 and Its
Interactions with the DH Domain
PH2 docks its surface composed of the
b1–b4 sheet and the C-terminal helix
onto the substrate-binding surface of
the DH domain (Figure 5). Gln932 and
Arg1017 in PH2 make polar interactionswith His690 and Glu545 in the DH domain, respectively.
Tyr1013 in PH2 packs its aromatic ring with Phe541 in the DH
domain (Figure 5A). At the other end of the interface, strands
b2–4 and the connecting loops in PH2 contribute numerous
hydrophobic interactions to the PH2/DH interface (Figure 5B).
Particularly, Trp951, Val953, Phe960, Tyr962, Tyr969, and
Pro970 in PH2 form a large hydrophobic patch, which packs
against the surface around Tyr674 in the loop between helices
a4 and a5 in the DH domain. The PH2/DH interface buries
2,170 A˚2 surface area and covers virtually the entire substrate-
binding face of the DH domain, rendering it completely inacces-
sible to the substrate. Previous studies have shown that
Src-mediated tyrosine phosphorylation of FARP2 contributes
to its activation (Fukuhara et al., 2004; Fukuyama et al., 2005;
Miyamoto et al., 2003; Murata et al., 2006). Intrinsic dynamics
of the FARP2 protein may transiently expose some of the
tyrosine residues in the PH2/DH interface, allowing them to be
phosphorylated. This would lead to disruption of the interface,
providing a plausible mechanism for phosphorylation-triggered
activation of the GEF activity.
A search by Dali suggested that the structure of PH2 in FARP2
is most similar to the PH domain in DAPP1/PHISH (PDB ID code:
1FAO) (root-mean-square deviation [rmsd] of 1.5 A˚ for 85 aligned
Ca atoms) (Ferguson et al., 2000) (Figure S4A). It deviates from
PH1 substantially, mainly at strands b6–b7 and the b3-4 loop
(Figure S4B). In contrast to the relatively straight conformation
in PH1, the b3-4 loop plane in PH2 is nearly orthogonal to the
axes of the strands. As described above, the b3-4 loop in PH2
uses this conformation to make a major contribution to theª2013 Elsevier Ltd All rights reserved 359
Figure 4. Structure of the PH1-PH2 Linker
and Its Interactions with PH1 and PH2
(A) Interactions made by the first helix in the PH1-
PH2 linker.
(B) Interactions made by the strand and the
second helix in the PH1-PH2 linker.
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Crystal Structures of Autoinhibited FARP2PH2/DH interface (Figure 5B). Another notable difference is
at the potential PtdInsP(s) binding site. PH2 only has three
positively charged residues at this site (Figure S4A), suggesting
that it may have lower binding affinity and/or different specific-
ities for PtdInsP(s).
Substrate Specificity and Activity Measurements
We performed sequence and structural comparisons of FARPs
with other well-studied Dbl-family GEFs to identify residues
that are potentially involved in determining substrate specificity.
One major specificity determining residue in the DH domain is
located in helix a5 (Snyder et al., 2002). Although most Cdc42-
specific GEFs contain a leucine residue at this position
(Leu1376 in intersectin), which makes favorable interactions
with Phe56 in Cdc42, Rac1-specific GEFs contain an isoleucine
residue to accommodate the larger side chain of Trp56 in Rac1.
RhoA-specific GEFs often possess one or more positively
charged residues in the loop between helices a4 and a5, which
interact with the negatively charged patch consisting of Asp45
and Glu54 in RhoA (Kristelly et al., 2004; Oleksy et al., 2006;
Snyder et al., 2002). Both FARP2 and FARP1 have a leucine
(Leu682 and Leu683, respectively) at the Phe/Trp-interacting
position and lack the RhoA-interacting positively charged resi-
dues in the a4-a5 loop (Figure 1D), indicating that they may
prefer Cdc42 as their substrates. However, as mentioned above,
various previous experimental investigations have led to conflict-
ing results regarding the substrate specificities of FARPs.
We used an in vitro GEF assay to measure the activity of
FARP2 to Rac1 and Cdc42, each of which has been identified
as the exclusive substrate of FARP2 by different studies (Fuku-
hara et al., 2004; Fukuyama et al., 2005; Kubo et al., 2002; Miya-
moto et al., 2003; Murata et al., 2006; Toyofuku et al., 2005). We
designed a series of constructs to test the autoinhibition mech-
anisms revealed by the structures. These include both the
wild-type and the Leu730Arg/Leu733Gln (L730R/L733Q) double
mutants of the isolated DH domain and the DH-PH domains. The
L730R/L733Q mutations are expected to disrupt the pseudo-
substrate-like interactions made by helix a6C, whereas trunca-
tion of PH1 and PH2 releases the substrate-binding surface
occupied by these domains. The results showed that none of
these FARP2 proteins has detectable GEF activity to either
Rac1 or Cdc42 (Figures S5A and S5B). Additional assays using
nine other RhoGTPases also failed to detect significant activity
for FARP2 (Figures S5C–S5K).
The lack of activity may be partially due to the low intrinsic
activity of FARP2 as a result of replacement of several key cata-360 Structure 21, 355–364, March 5, 2013 ª2013 Elsevier Ltd All rights reservedlytic residues in the DH domain
mentioned above (Figure 1D). It is also
possible that the tested mutations are
not sufficient for releasing the autoinhibi-
tion and meanwhile stabilizing the activeconformation. Particularly, the proper orientation of helix a6,
which is known to be critical for the activity of many RhoGEFs
(Rossman et al., 2005), may not be achieved by the L730R/
L733Q mutations. In addition, it has been shown that FARP2
activation involves membrane localization, binding of activators
and tyrosine phosphorylation (Fukuhara et al., 2004; Fukuyama
et al., 2005; Miyamoto et al., 2003; Murata et al., 2006), which
were missing in the in vitro assays.
We therefore turned to a GTPase pull-down assay to measure
the GEF activity of FARP2 in cells. We introduced the same
L730R/L733Q double mutations to both the full-length (FL) and
a PH2-truncated version (DPH2) of FARP2. The results showed
that none of these FARP2 constructs significantly increased
the levels of GTP-bound Cdc42 in cells (Figure 6A). FARP2
may be indeed not active to Cdc42, or the assay condition
used here does not allow detection of this activity, as it has
been reported that Cdc42 activation is difficult to detect through
the pull-down assay (Gotthardt and Ahmadian, 2007; Mitin et al.,
2007; Nalbant et al., 2004). In contrast, expression of the FL
construct increased the level of GTP-bound Rac1 when
compared with the control (Figure 6B). Similar activation levels
were also observed for both DPH2 and FLL730R/L733Q. Notably,
GTP-bound Rac1 increased much more substantially when
DPH2L730R/L733Q was expressed. These results demonstrate
that Helix a6C and PH2 domain each can independently inhibit
GEF activity of FARP2, and full activation requires releasing of
both these two inhibitory elements.
Conclusions
Our crystal structures of FARPs reveal a complex autoinhibitory
mechanism that involves multiple domains. The results of the
cell-based activity assays suggest that helix a6C and PH2
are able to exert their inhibitory effects independently of each
other. The autoinhibition is likely strengthened by the interdo-
main interactions among the autoinhibitory domains and the
two well-structured linkers. This mechanism differs from the
multilayered autoinhibition of Vav, in which the secondary
interactions all exert their effects indirectly through the core
inhibitory element, the so-called acidic domain adjacent to the
DH domain (Yu et al., 2010). These complex autoinhibition
mechanisms raise the question of how the GEFs are activated
efficiently in response to upstream signals. In the case of Vav,
activation is achieved by stepwise phosphorylation events. Initial
phosphorylations disrupt the secondary autoinhibition, facili-
tating the subsequent phosphorylation and eventual release of
the acidic domain. FARP2 has been shown to be activated by
Figure 5. Interface between PH2 and the DH
Domain
See also Figure S4.
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Crystal Structures of Autoinhibited FARP2Src-mediated phosphorylation, but the sites of phosphorylation
and how it triggers activation are not known (Fukuhara et al.,
2004; Fukuyama et al., 2005; Miyamoto et al., 2003). The struc-
ture of the DH-PH-PH domains of FARP2 reveals a number of
tyrosine residues at the PH2/DH interface. Transient exposure
of these residues due to intrinsic dynamics of the protein may
allow them to be phosphorylated by Src or other kinases, leading
to disruption of the PH2/DH interface and initiation of the activa-
tion process.
Tyrosine phosphorylation alone is unlikely capable of trig-
gering full activation of FARP2 because of the pseudosub-
strate-like autoinhibition by helix a6C, which does not contain
any tyrosine residue. The weakened autoinhibition upon phos-
phorylation may facilitate binding of an allosteric activator,
which converts FARP2 to the active conformation in a manner
similar to activation of p63RhoGEF by Gaq (Lutz et al., 2007).
Mapping the sequence conservation between FARP1 and
FARP2 to the FARP2 DH-PH-PH structure reveals a prominent
conserved surface patch on the side of the two PH domains
distal to the DH domain (Figure S2C), which may serve as the
binding site for the allosteric activator. The Ras homolog Rap
has been shown to stimulate FARP2 activity in the nectin
signaling pathway, although it is not clear whether it does so
through direct interaction (Fukuyama et al., 2005). Consistent
with our analyses, FARP2 activation in this pathway appears
to require both Src-mediated phosphorylation and the presence
of GTP-bound active Rap, whereas either one alone is insuffi-
cient (Fukuyama et al., 2005). Although it has been suggested
that semaphorin-triggered dissociation of FARP2 from plexin
leads to activation of FARP2 (Toyofuku et al., 2005), the tight
autoinhibition of FARPs shown here argues that dissociation
from plexin per se is unlikely to induce spontaneous activation.
We have recently shown that plexins are noncanonical
GTPase-activating proteins for Rap and can cause localized
inactivation of Rap (Wang et al., 2012). Dissociation from plexin
may allow FARP2 to diffuse to areas with higher levels of active
Rap, providing a putative mechanism for semaphorin/plexin-
controlled FARP2 activation.
Lastly, the lack of GEF activity in the in vitro assays and the
replacement of key catalytic residues in the DH domain indicate
the possibility that FARP2 has impaired GEF activity and func-
tions in signal transduction primarily by acting as a protein-
protein interaction module. For example, FARP2 may bind and
activate other RhoGEFs in the cell, and thereby indirectly
activate RhoGTPases. The conserved surface patch on the
DH-PH-PH domains (Figure S2C) may mediate such bindingsStructure 21, 355–364, March 5, 2013or make intramolecular interactions
with the N-terminal FERM domain and
control its interactions with other pro-
teins. Regardless of whether FARPs are
active GEFs or scaffold-like proteins, the
structures presented here provide a
framework for future analyses of the inter-actions of FARPs with their binding partners and the mecha-
nisms by which they regulate various signaling pathways.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The coding regions of the DH domain (residues 536–749), the DH-PH domains
(residues 536–860), and the DH-PH-PH domains (residues 536–1032) of
mouse FARP2 and the DH-PH-PH domains (residues 538–1034) of human
FARP1 were all cloned into a modified pET-28(a) vector (Novagen, Madison,
WI, USA) that encodes an N-terminal His6-tag followed by a recognition
site for human rhinovirus 3C protease. Point mutations were introduced by
QuikChange reactions (Stratagene, La Jolla, CA, USA). The plasmids were
transformed into the E. coli strain BL21(DE3), and protein expression was
induced by 0.1 mM IPTG at 16C overnight. Seleno-methoinine replaced
proteins were expressed in the same bacterial strain using the protocol as
described by Van Duyne et al. (1993). The proteins were purified by using
a 1 ml HisTrap column (GE Healthcare, Waukesha, WI, USA) and treated
with recombinant human rhinovirus 3C protease at 4C overnight to remove
the N-terminal tag. Further purification was performed by using a Superdex
200 HR 10/30 (GE Healthcare) equilibrated with the buffer containing 20 mM
Tris (pH 8.0), 150mMNaCl, 10%glycerol, and 2mMDTT. The purified proteins
were concentrated and stored at 80C.
Crystallization and Structure Determination
All crystallization experiments were conducted through hanging drop vapor
diffusion at 20C. The seleno-methionine replaced protein of the DH domain
of FARP2 at 9 mg/ml was crystallized in 100 mM HEPES (pH 7.0) and 1.5 M
LiSO4. The DH-PH-PH domains of FARP2 at 7 mg/ml was crystallized in
100mMMMT (containing DL-malic acid, MES, and Tris base at the 1:2:2molar
ratio and adjusted to pH 7.0 by NaOH titration), 20% PEG3350, and 0.2M
Li2SO4. The seleno-methionine DH-PH-PH domains of FARP1 at 15 mg/ml
was crystallized in 100 mM MES (pH 6.4), 0.2 M magnesium formate, and
14% PEG3350. Crystals were flash frozen in the crystallization buffers supple-
mented with 25% glycerol. All diffraction data were collected at 173C at
beamline 19ID at advanced photon source (Argonne National Laboratory
[APS]). Data were indexed, reduced, and scaled using the HKL2000 package
(Otwinowski and Minor, 1997). Detailed information of the crystals and data
collection statistics are summarized in Table 1.
The structure of the FARP2 DH domain was solved by single-wavelength
anomalous dispersion (SAD) by using the Autosol module of the Phenix
program package (Adams et al., 2002). The initial experimental map showed
clear density for all nine protomers of the DH domain in the asymmetric unit.
Attempts of solving the structure of the DH-PH-PH domains of FARP2
through molecular replacement by using various individual DH and PH
domain structures as searching models failed. We then used a model of the
entire DH-PH-PH module assembled based on the experimental electron
density map of the FARP1 structure (see below). Two copies of the ensemble
model were located in the asymmetric unit by Phaser in the Phenix package
(McCoy et al., 2007). Strong difference density appeared at the potential
PtdInsP(s) binding site in PH1 after a few rounds of refinement, suggesting
binding of a certain small molecule compound. Attempts at determining the
identity of the compound by mass spectrometry failed. Several waterª2013 Elsevier Ltd All rights reserved 361
Figure 6. Cell-Based GEF Activity Assays for FARP2
(A) Assays of FARP2 activity toward Cdc42. Representative blots from five
independent experiments are shown. Quantifications of the results are in the
lower panel. The level of GTP-bound Cdc42 normalized by the total expression
level from cells transfected with the control vector is arbitrarily set to one.
Levels of GTP-bound Cdc42 from cells expressing various FARP2 constructs
are presented by fold increase (mean ± SE of the five experiments) over
the control. FL, full-length FARP2; FLL730R/L733Q, full-length FARP2 with the
L730R/L733Q mutations; DPH2, PH2-truncated FARP2; DPH2L730R/L733Q,
PH2-truncated FARP2 with the L730R/L733Q mutations. Lower bands in the
FLAG-FARP2 blots are likely degradation products of FARP2.
(B) Assays of FARP2 activity toward Rac1. Data are presented as in (A). The
p value was calculated from Student’s t test.
See also Figure S5.
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Crystal Structures of Autoinhibited FARP2molecules were placed in the density for refinement and are included in the
final model.
A SAD data set to 4.1 A˚ resolution was collected on a crystal of the seleno-
methionine replaced DH-PH-PH domains of FARP1. The Phenix Autosol
module was used to locate the selenium sites and generate the initial experi-
mental electron density map. Despite the low resolution, the map clearly
defined two protomers of the DH-PH-PH domains in the asymmetric unit.
Two copies of the structure of the FARP2 DH domain were docked manually
into the density. Structures of the PH domains from PEPP-3 (PDB ID code:
2D9Y) and Grp1 (PDB ID code: 1FHW) were then docked as PH1 and PH2,
respectively. The three docked domains served as the ensemble model for
the entire DH-PH-PH module, which was used for solving the structure of
the FARP2 DH-PH-PH domains by molecular replacement. After the higher
resolution structure of FARP2 was refined, the final model was docked into
the SAD electron density of the FARP1 crystal. Because of the low resolution,
many side chains and less well-ordered loops were removed from the model
before refinement. Rigid body refinement with each domain treated as one
rigid body led to excellent fit without significant changes of the overall organi-
zation. Subsequent refinement steps were performed by using the mlhl target
function in Phenix, with tight restraints to prevent overfitting.
Model building and structure refinement were performed by using the
programs Coot and Phenix, respectively (Adams et al., 2002; Emsley and
Cowtan, 2004). Refinement statistics are shown in Table 1. Buried surface
area was calculated in the CNS package (Bru¨nger et al., 1998). Molecular
structure figures were rendered by the program Pymol (the PyMOL Molecular362 Structure 21, 355–364, March 5, 2013 ª2013 Elsevier Ltd All righGraphics System, Schro¨dinger). Sequence alignmentswere rendered by using
ESPript (Gouet et al., 1999).
In Vitro GEF Activity Assay
The in vitro GEF assays were based on Eberth and Ahmadian (2009). Cdc42,
Rac1, RhoA, or RhoC preloaded with N-methylanthraniloyl-GDP (mant-GDP)
at 200 nM was incubated with the reaction buffer containing 400 nM unla-
beled GDP, 50 mM HEPES (pH 7.5), 100 mM NaCl, and 5 mM MgCl2. Purified
proteins from various constructs of FARP2 were added to the final concen-
tration of 10 mM. The salmonella virulence effector SopE, a highly active
GEF, was used at 0.5 mM as a positive control. Decrease of the fluorescence
signal at 440 nm with 360 nm excitation was monitored by a Fluorolog-3
spectrofluorometer at 25C. For assays with RhoB, RhoE, RhoG, Rho6,
Rho7, Rif, and TCL, mant-GDP at 200 nM was in the reaction buffer instead,
and increase of the fluorescence signal upon its binding to the GTPases was
monitored.
Cell-Based GEF Activity Assay
Cell-based GEF activity assays of FARP2 toward Rac1 and Cdc42 were based
on the selective binding of GTP-bound Rac1 and Cdc42 by Cdc42/Rac1 inter-
active binding (CRIB) motif from p21 activated kinase (Malliri et al., 2002). All
the FARP2 constructs with a C-terminal FLAG-tag were cloned into the
pcDNA3.1(+) vector (Invitrogen, Carlsbad, CA, USA). Full-length Rac1 and
Cdc42 with a N-terminal Myc-tag were also cloned into pcDNA3.1(+).
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen)
and transfected at 80% confluency in 6-well plates using Fugene HD transfec-
tion reagent (Promega, Madison, WI, USA) in accordance with the manufac-
turer’s instruction. The amounts of plasmids for transfection were optimized
to ensure equal protein expressions among different transfection sets. For
Rac1 transfections, 0.5 mg of the Rac1 plasmid was used. The following
amounts of FARP2 plasmids were used: full-length wild-type (FL), 3.75 mg;
FL with the L730R/L733Q mutations (FLL730R/L733Q), 3.75 mg; FARP2 with
PH2 truncated (DPH2, residues 1–857), 5.5 mg; DPH2L730R/L733Q, 5.5 mg. For
Cdc42, 0.25 mg and 0.50 mg of the Cdc42 plasmid were used when transfected
with andwithout the FARP2 plasmids, respectively. The amounts of the FARP2
plasmids were: FL, 4 mg; FLL730R/L733Q, 4 mg; DPH2, 5.75 mg; DPH2L730R/L733Q,
5.75 mg. The empty pcDNA3.1(+) plasmid was added to adjust the final total
amount of DNA to 6 mg per transfection.
Twenty-four hours after transfection, cells were serum starved by replacing
the original medium with DMEM containing 0.1% serum for additional 24 hr.
Cells were then lysed in the pull-down buffer (50 mM HEPES [pH 7.2],
150 mM NaCl, 2 mM MgCl2, 5% glycerol, 1% (w/v) Triton X-100, and 2 mM
DTT) containing a protease inhibitor tablet (Pierce, Rockford, IL, USA) at 1
tablet/10 ml. Lysates were cleared by centrifugation at 14,000 rpm for
10 min at 4C and incubated with glutathione sepharose beads loaded with
purified GST-CRIB fusion (10 mg) for 1 hr at 4C. Beads were washed three
times with the pull-down buffer and resuspended in a SDS-PAGE sample
buffer. The samples were run on SDS-PAGE and analyzed by western blots.
Expression levels of FARP2 were detected with the mouse monoclonal anti-
FLAG antibody M2 (Sigma-Aldrich, St. Louis, MO, USA). RhoGTPases were
detected with a mouse monoclonal anti-Myc primary antibody (Cell Signaling,
Danvers, MA, USA). A rabbit anti-mouse IgG HRP-conjugated antibody (Cell
Signaling) was used as the secondary antibody. Levels of GTP-bound Rac1
or Cdc42 were quantified and normalized by the total expression levels of
the proteins.
ACCESSION NUMBERS
Atomic coordinates and structure factors for the DH domain of FARP2, the DH-
PH-PH domains of FARP2, and the DH-PH-PH domains of FARP1 have been
deposited in the Protein Data Bank (http://www.pdb.org) with the accession
codes 4GYV, 4GZU, and 4H6Y, respectively.
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